Bendamustine in Chinese Participants With Non-Hodgkin Lymphoma
Study Title
- Bendamustine in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment
Teva Identifier
- C18083/3076
ClinicalTrials.gov Identifier
- NCT01596621
Study Status
- Completed
Trial Condition(s)
- Non-Hodgkin Lymphoma
Interventions
- Drug: Bendamustine hydrochloride
Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
Gender
- Female, Male
Age Range
- 18 Years and older
Trial Duration
- August 6, 2012 - April 28, 2017
Phase
- Phase 3
Study Type
Interventional
